Insider Selling: Takeda Pharmaceutical (NYSE:TAK) Insider Sells 3,978 Shares of Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Elaine Mary Shannon sold 3,978 shares of Takeda Pharmaceutical stock in a transaction on Monday, August 10th. The shares were sold at an average price of $17.10, for a total value of $68,023.80. Following the completion of the transaction, the insider owned 63,333 shares of the company’s stock, valued at approximately $1,082,994.30. The trade was a 5.91% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Price Performance

Shares of TAK stock traded down $0.06 during trading hours on Wednesday, hitting $17.42. 2,004,364 shares of the company’s stock were exchanged, compared to its average volume of 4,402,927. Takeda Pharmaceutical Co. has a 52 week low of $12.99 and a 52 week high of $18.90. The stock has a market cap of $55.82 billion, a price-to-earnings ratio of 51.24 and a beta of -0.08. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.14 and a quick ratio of 0.62. The stock’s 50-day moving average is $16.49 and its 200-day moving average is $17.13.

Takeda Pharmaceutical (NYSE:TAK) last announced its earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share (EPS) for the quarter. The company had revenue of $6.90 billion for the quarter. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. As a group, research analysts forecast that Takeda Pharmaceutical Co. will post 3.01 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Wall Street Zen upgraded Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Zacks Research raised shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 4th. Finally, Weiss Ratings lowered shares of Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, July 30th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Takeda Pharmaceutical currently has a consensus rating of “Hold”.

Hedge Funds Weigh In On Takeda Pharmaceutical

Several hedge funds and other institutional investors have recently made changes to their positions in TAK. Private Trust Co. NA raised its position in Takeda Pharmaceutical by 84.7% during the fourth quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock worth $27,000 after acquiring an additional 783 shares in the last quarter. Parkside Financial Bank & Trust raised its holdings in shares of Takeda Pharmaceutical by 192.2% in the 4th quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock valued at $40,000 after purchasing an additional 1,684 shares during the period. SHP Wealth Management acquired a new stake in Takeda Pharmaceutical in the 4th quarter valued at about $42,000. Caitong International Asset Management Co. Ltd grew its holdings in Takeda Pharmaceutical by 313.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company’s stock worth $48,000 after purchasing an additional 2,328 shares during the period. Finally, Northwestern Mutual Wealth Management Co. increased its position in Takeda Pharmaceutical by 56.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock worth $55,000 after buying an additional 1,292 shares during the last quarter. 9.17% of the stock is owned by institutional investors.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.